X
NKTR icon

Xponance’s Nektar Therapeutics NKTR Stock Holding History

Xponance’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-813
Closed -$8.29K – 1531
2025
Q1 		$8.29K Buy
813
+20
+3% +$261 ﹤0.01% 1441
2024
Q4 		$11.1K Buy
793
+73
+10% +$1.29K ﹤0.01% 1439
2024
Q3 		$14K Sell
720
-44
-6% -$839 ﹤0.01% 1385
2024
Q2 		$14.2K Buy
+764
New +$16.1K ﹤0.01% 1313
2023
Q2 		– Sell
-689
Closed -$7.27K – 1278
2023
Q1 		$7.27K Hold
689
– – ﹤0.01% 1234
2022
Q4 		$23.4K Buy
689
+11
+2% +$532 ﹤0.01% 1210
2022
Q3 		$33K Buy
+678
New +$40.3K ﹤0.01% 1166
2021
Q4 		– Sell
-1,376
Closed -$371K – 1187
2021
Q3 		$371K Sell
1,376
-46
-3% -$11.1K 0.01% 995
2021
Q2 		$366K Buy
1,422
+142
+11% +$39.3K 0.01% 1022
2021
Q1 		$384K Buy
1,280
+26
+2% +$8.09K 0.01% 886
2020
Q4 		$320K Sell
1,254
-2
-0.2% -$517 0.01% 933
2020
Q3 		$312K Buy
1,256
+185
+17% +$58.2K 0.01% 843
2020
Q2 		$372K Buy
+1,071
New +$334K 0.01% 748

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Xponance's NKTR Position: Q2 2025 in Review

Xponance sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 813 shares — an estimated $8.29K sold.

Xponance first reported a position in NKTR in Q2 2020 and held it in 13 quarters. The position peaked at $384K in Q1 2021. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • Xponance reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Xponance sold 813 Nektar Therapeutics shares in Q2 2025, an estimated $8.29K.
  • Xponance first reported a position in Nektar Therapeutics in Q2 2020 and held it in 13 quarters.
  • Xponance's Nektar Therapeutics position peaked at $384K in Q1 2021.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Xponance's 13F filing for Q2 2025, filed 14 Aug 2025.